MedTrace Logo

A Phase II Safety and Tolerability Study With SEN0014196

NCT01521585 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2015-11-25

No results posted yet for this study

Summary

The principal aim of this study is to obtain safety and tolerability data when SEN0014196 is administered orally over 12 weeks to male and female patients with Huntington's Disease.

Conditions

Interventions

DRUG

SEN0014196

50 mg oral once daily tablet

DRUG

SEN0014196

200 mg oral once daily tablet

DRUG

Placebo

oral once daily tablet

Sponsors & Collaborators

  • Siena Biotech S.p.A.

    lead INDUSTRY

Principal Investigators

  • Ralf Reilmann, MD · Dept. of Neurology, University of Münster - Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01521585 on ClinicalTrials.gov